SIOX VS NEPT Stock Comparison

Performance

SIOX
10/100

SIOX returned -58.25% in the last 12 months. Based on the other stocks in it's sector, it's performance is below average giving it a grade of 10 of 100.

NEPT
10/100

NEPT returned -98.27% in the last 12 months. Based on SPY's performance of -13.45%, its performance is below average giving it a score of 10 of 100.

Forecast

SIOX
82/100

The 38 analysts offering 12-month price forecasts for SIOX have an average target of 0, with a high estimate of 0 and a low estimate of 0 giving it a grade of 82 of 100.

NEPT

"Forecast" not found for NEPT

Technicals

SIOX
86/100

Based on a multitude of SIOX's technicals indicators, it receives a grade of 85 of 100.

NEPT
25/100

NEPT receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Volatility

SIOX
10/100

SIOX had a -3,007.89% lower max drawdown compared to SPY over the last 12 months giving it a grade of 10 of 100.

NEPT
34/100

NEPT has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

Dividend

SIOX
10/100

SIOX does not have a dividend payout ratio.

NEPT

"Dividend" not found for NEPT

Profit

SIOX
10/100

Could not get data for SIOX.

NEPT
13/100

Out of the last 20 quarters, NEPT has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Analyst Price Targets

SIOX

"Analyst Price Targets" not found for SIOX

NEPT
75/100

1 analysts offer 12-month price targets for NEPT. Together, they have an average target of 0, the most optimistic target put NEPT at 0 within 12-months and the most pessimistic has NEPT at 0.

Earnings

SIOX

"Earnings" not found for SIOX

NEPT
10/100

NEPT has missed earnings 10 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Sio Gene Therapies Inc. Common Stock Summary

Nasdaq / SIOX

Healthcare

Biotechnology

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Neptune Wellness Solutions Inc. Ordinary Shares Summary

Nasdaq / NEPT

Healthcare

Drug Manufacturers—Specialty & Generic

Neptune Wellness Solutions Inc. operates as an integrated health and wellness company in Canada, the United States, and internationally. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, MaxSimil, and NurturMe brands. The company also offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, including nutraceuticals, beauty and personal care products, and organic foods and beverages. In addition, it is involved in the extraction, purification, formulation, and manufacturing of health and wellness products. Further, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

Power up your portfolio